LifeMD Narrows Losses Amid Telehealth Revenue Surge

Ticker: LFMDP · Form: 10-Q · Filed: Nov 17, 2025 · CIK: 948320

Lifemd, INC. 10-Q Filing Summary
FieldDetail
CompanyLifemd, INC. (LFMDP)
Form Type10-Q
Filed DateNov 17, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentmixed

Sentiment: mixed

Topics: Telehealth, Digital Health, Weight Management, Liquidity Risk, Revenue Growth, Net Loss, Debt Repayment

Related Tickers: LFMD, LFMDP, TDOC, HIMS

TL;DR

**LifeMD is still bleeding cash despite revenue growth, but the WorkSimpli sale and debt repayment could be a lifeline if they can finally hit profitability.**

AI Summary

LifeMD, Inc. reported total revenues of $60,172,470 for the three months ended September 30, 2025, an increase from $53,272,294 in the prior year, primarily driven by a rise in telehealth revenue to $47,279,933 from $40,154,683. Despite revenue growth, the company posted a net loss attributable to LifeMD, Inc. common stockholders of $(4,582,680) for the quarter, an improvement from $(5,434,485) in the same period of 2024. For the nine months ended September 30, 2025, total revenues reached $186,975,039, up from $149,337,063, while the net loss attributable to common stockholders was $(7,939,247), significantly better than $(18,800,039) in the prior year. Key business changes include the expansion of its GLP-1 Weight Management Program in April 2023 and a non-GLP-1 treatment plan in September 2024. The company also sold its majority ownership in WorkSimpli to Lion Buyer, LLC on November 4, 2025, and repaid $14.0 million of the Avenue Credit Agreement on August 5, 2025. Risks include an accumulated deficit of $247.8 million and a working capital deficit of $15.6 million as of September 30, 2025, indicating ongoing liquidity challenges despite improved net loss figures.

Why It Matters

LifeMD's continued revenue growth in telehealth, particularly with its GLP-1 Weight Management Program, signals strong demand in a competitive market, potentially attracting investors looking for exposure to the booming digital health sector. However, the persistent accumulated deficit of $247.8 million and working capital deficit of $15.6 million raise concerns about long-term financial stability and capital requirements, which could impact employee morale and customer trust. The strategic divestiture of WorkSimpli suggests a focus on core telehealth operations, a move that could streamline the business but also removes a diversified revenue stream. Competitors like Teladoc Health and Hims & Hers Health will be watching LifeMD's ability to convert revenue growth into sustained profitability.

Risk Assessment

Risk Level: high — LifeMD, Inc. reported an accumulated deficit of approximately $247.8 million and a working capital deficit of approximately $15.6 million as of September 30, 2025. This significant working capital deficit, even with $14.4 million of deferred revenue, indicates substantial liquidity challenges and a reliance on external funding, evidenced by the $18,719,721 repayment of debt instruments and $8,721,717 from common stock sales under an ATM during the nine months ended September 30, 2025.

Analyst Insight

Investors should monitor LifeMD's cash flow from operations and future debt obligations closely, especially following the WorkSimpli divestiture. While revenue growth is positive, the persistent accumulated deficit and working capital deficit suggest high financial risk; consider waiting for clear signs of sustained profitability and positive free cash flow before investing.

Financial Highlights

debt To Equity
N/A
revenue
$60,172,470
operating Margin
-3.3%
total Assets
$65,983,378
total Debt
$0
net Income
$(4,582,680)
eps
$(0.10)
gross Margin
87.7%
cash Position
$23,785,771
revenue Growth
+12.9%

Revenue Breakdown

SegmentRevenueGrowth
Telehealth revenue, net$47,279,933+17.7%
WorkSimpli revenue, net$12,892,537-1.7%

Key Numbers

Key Players & Entities

FAQ

What were LifeMD, Inc.'s total revenues for the quarter ended September 30, 2025?

LifeMD, Inc. reported total revenues, net, of $60,172,470 for the three months ended September 30, 2025, an increase from $53,272,294 in the same period of 2024.

How much was LifeMD, Inc.'s net loss attributable to common stockholders for the nine months ended September 30, 2025?

The net loss attributable to LifeMD, Inc. common stockholders for the nine months ended September 30, 2025, was $(7,939,247), a significant improvement compared to $(18,800,039) for the same period in 2024.

What is LifeMD, Inc.'s accumulated deficit as of September 30, 2025?

As of September 30, 2025, LifeMD, Inc. had an accumulated deficit of approximately $247.8 million, indicating a history of operating losses.

Did LifeMD, Inc. make any significant debt repayments during the nine months ended September 30, 2025?

Yes, LifeMD, Inc. made a repayment of debt instruments totaling $18,719,721 during the nine months ended September 30, 2025, including $14.0 million of the Avenue Credit Agreement on August 5, 2025.

What was the impact of the WorkSimpli sale on LifeMD, Inc.?

LifeMD, Inc. sold its majority ownership interest in WorkSimpli to Lion Buyer, LLC on November 4, 2025, which is a subsequent event to the reporting period. This divestiture is expected to streamline the company's focus on its core telehealth business.

What new programs did LifeMD, Inc. launch in its telehealth offerings?

LifeMD, Inc. launched its GLP-1 Weight Management Program in April 2023 and expanded it in September 2024 with a personalized, non-GLP-1 treatment plan consisting of metformin, bupropion, and topiramate.

What is LifeMD, Inc.'s current working capital position?

As of September 30, 2025, LifeMD, Inc. had a working capital deficit of approximately $15.6 million. This includes approximately $14.4 million of deferred revenue expected to be recognized within 12 months.

How much cash did LifeMD, Inc. have at the end of the period?

LifeMD, Inc. reported cash of $23,785,771 as of September 30, 2025, a decrease from $35,004,924 at the beginning of the period.

What is the significance of the Series A Preferred Stock for LifeMD, Inc.?

LifeMD, Inc. has 1,400,000 shares of Series A Preferred Stock issued and outstanding with a liquidation value of approximately $35.8 million as of September 30, 2025. The company paid preferred stock dividends of $776,563 for the three months and $2,329,688 for the nine months ended September 30, 2025.

What are the primary revenue streams for LifeMD, Inc.?

LifeMD, Inc.'s primary revenue streams are Telehealth revenue, net, which was $47,279,933 for the three months ended September 30, 2025, and WorkSimpli revenue, net, which was $12,892,537 for the same period, although WorkSimpli was subsequently sold.

Risk Factors

Industry Context

LifeMD operates in the rapidly growing telehealth and digital health market, which has seen increased adoption post-pandemic. Key trends include the expansion of chronic disease management programs, direct-to-consumer models, and the integration of AI for diagnostics and patient engagement. The competitive landscape is intensifying with established healthcare providers, specialized digital health startups, and large technology companies entering the space.

Regulatory Implications

The telehealth sector faces evolving regulatory landscapes concerning data privacy (HIPAA), prescribing practices, state licensing, and reimbursement policies. LifeMD must navigate these complexities to ensure compliance and avoid penalties, which could impact service delivery and financial performance.

What Investors Should Do

  1. Monitor cash flow and working capital trends closely.
  2. Evaluate the sustainability of telehealth revenue growth.
  3. Assess the impact of the WorkSimpli divestiture.
  4. Scrutinize expense management strategies.

Key Dates

Glossary

Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. It represents a deficit in retained earnings. (Indicates the company's historical unprofitability, with a significant deficit of $247.8 million as of September 30, 2025.)
Working capital deficit
A situation where a company's current liabilities exceed its current assets. It suggests potential short-term liquidity issues. (LifeMD has a working capital deficit of $15.6 million as of September 30, 2025, highlighting ongoing liquidity challenges.)
Telehealth revenue, net
Revenue generated from providing healthcare services remotely through digital communication technologies. (This is LifeMD's primary revenue driver, showing significant growth to $47.3 million for the quarter ended September 30, 2025.)
Non-controlling interest
The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership stake of external shareholders in consolidated subsidiaries. (Appears on the balance sheet and statement of operations, reflecting the portion of net income/loss belonging to other owners in consolidated entities.)
Loss on debt extinguishment
A loss recognized when a company repays or retires debt before its scheduled maturity date, often involving a premium payment or unamortized issuance costs. (LifeMD recorded a loss of $1.16 million related to debt extinguishment during the nine months ended September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year, LifeMD demonstrated robust revenue growth, with total revenues increasing by 12.9% for the three months ended September 30, 2025, and 25.2% for the nine-month period. This growth was primarily fueled by its telehealth segment. While the net loss attributable to common stockholders significantly improved, narrowing from $(5.4) million to $(4.6) million for the quarter and from $(18.8) million to $(7.9) million for the nine months, the company still operates at a net loss. Key financial risks, such as the accumulated deficit and working capital deficit, remain prominent, although the repayment of debt indicates a focus on financial restructuring.

Filing Stats: 4,563 words · 18 min read · ~15 pages · Grade level 14.9 · Accepted 2025-11-17 16:52:52

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES 43 2 PART I – FINANCIAL INFORMATION Item 1. Financial Statements LIFEMD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current Assets Cash $ 23,785,771 $ 35,004,924 Accounts receivable 9,244,321 10,854,084 Product deposit 370,518 40,763 Inventory 3,432,382 2,797,358 Other current assets 4,252,613 3,672,231 Total Current Assets 41,085,605 52,369,360 Non-current Assets Equipment, net 2,584,829 1,479,184 Right of use assets, net 5,578,992 6,400,596 Capitalized software, net 15,175,634 13,816,501 Intangible assets, net 1,558,318 2,030,656 Total Non-current Assets 24,897,773 23,726,937 Total Assets $ 65,983,378 $ 76,096,297 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable $ 19,554,735 $ 16,009,484 Accrued expenses 22,079,805 22,811,763 Current operating lease liabilities 673,482 508,537 Current portion of convertible long-term debt - 8,444,444 Deferred revenue 14,355,531 19,625,940 Total Current Liabilities 56,663,553 67,400,168 Long-term Liabilities Convertible long-term debt, net - 9,885,057 Noncurrent operating lease liabilities 5,851,673 6,265,192 Contingent consideration 100,000 100,000 Total Liabilities 62,615,226 83,650,417 Commitments and contingencies (Note 11) - Stockholders' Equity (Deficit) Series A Preferred Stock, $ 0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $ 35.8 million as of September 30, 2025 and December 31, 2024 140 140 Common Stock, $ 0.01 par value; 100,000,000 shares authorized, 46,686,350 and 42,293,907 shares issued, 46,583,310 and 42,190,867 outstanding as of September 30, 2025 and December 31, 2024, respectively 466,864 422,939 Additional paid-in capital 248,801,209 230,508,339 Accumulated deficit ( 247,790,178 ) ( 239,850,931 ) Tr

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing